Insider Transaction: Josh Mandel-Brehm Acquires Stock Options in Camp4 Therapeutics Corp

This SEC filing details a transaction by Josh Mandel-Brehm, CEO and Director of Camp4 Therapeutics Corp. On April 1, 2026, Mandel-Brehm was granted 580,000 stock options with an exercise price of $4.46 per share. These options are exercisable immediately but vest in equal monthly installments over four years, commencing from the grant date. The options have an expiration date of March 31, 2036. This transaction is classified as an acquisition of securities by an insider. The filing indicates that the shares underlying the option vest over a four-year period starting from the grant date.